Ascidian Therapeutics, Inc
Clinical trials sponsored by Ascidian Therapeutics, Inc, explained in plain language.
-
Gene therapy injection aims to halt blinding eye disease
Disease control Recruiting nowThis early study tests a new gene therapy called ACDN-01 for people with Stargardt disease, a genetic condition that leads to progressive vision loss. The therapy is given as a one-time injection under the retina. The main goals are to check safety and find the right dose, with a…
Phase: PHASE1, PHASE2 • Sponsor: Ascidian Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New study seeks volunteers for future eye disease treatment
Knowledge-focused Recruiting nowThis prescreening study aims to identify up to 50 people with ABCA4-related retinopathy, including Stargardt disease, for possible participation in future ACDN-01 clinical trials. Participants will undergo genetic testing and various eye exams to confirm their condition. This is …
Sponsor: Ascidian Therapeutics, Inc • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC